The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | D | Dermatologicals | |
| 2 | D11 | Other dermatological preparations | |
| 3 | D11A | Other dermatological preparations | |
| 4 | D11AH | Agents for dermatitis, excluding corticosteroids | |
| 5 | D11AH10 |
| Active Ingredient | Description | |
|---|---|---|
| Lebrikizumab |
Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4RĪ±)/ IL-13 receptor alpha 1 (IL-13RĪ±1) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13RĪ±2 or decoy receptor), which allows the internalisation of IL-13 into the cell. |
